Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „budesonide“
Suchtreffer
Begriffe & Kennungen
GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.3 Contraindications · 2
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.3 · 5 Hypersensitivity to the active substances or the excipient listed in section 6.1.
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.3 · Hypersensitivity to the active substances or the excipient listed in section 6.1.
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.4 Special warnings and precautions for use · 2
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 Interaction with other medicinal products and other forms of interaction · 2
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · 24 outweighs the increased risk of systemic corticosteroid adverse reactions, in which case patients should be
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · 9 Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadin
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Budesonide and formoterol have not been observed to interact with any other medicinal products used in the tre
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Budesonide and formoterol have not been observed to interact with any other medicinal products used in the tre
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Concomitant treatment with monoamine oxidase inhibitors including medicinal products with similar properties s
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Concomitant treatment with monoamine oxidase inhibitors including medicinal products with similar properties s
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine)
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Concomitant use of other β adrenergic medicinal products and anticholinergic medicinal products can have a pot
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Concomitant use of other β adrenergic medicinal products and anticholinergic medicinal products can have a pot
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glyco
Eintrag öffnenGoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) · 4.5 · Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glyco
Eintrag öffnen